The knowns and unknowns of teprotumumab for thyroid eye disease. (2021)

First Author: Bednarczuk T
Attributed to:  Plasma-cell depletion therapy for severe Graves' disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-8587(21)00076-0

PubMed Identifier: 33865499

Publication URI: http://europepmc.org/abstract/MED/33865499

Type: Journal Article/Review

Volume: 9

Parent Publication: The lancet. Diabetes & endocrinology

Issue: 6

ISSN: 2213-8587